{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:26:54Z","timestamp":1783618014313,"version":"3.55.0"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.critrevonc.2018.02.003","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T18:34:36Z","timestamp":1518114876000},"page":"41-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature"],"prefix":"10.1016","volume":"124","author":[{"given":"Ombretta","family":"Annibali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariasanta","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Avvisati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Siragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2018.02.003_bib0005","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1182\/blood-2009-07-231084","article-title":"The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase","volume":"114","author":"Abbott","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0010","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.thromres.2016.03.006","article-title":"Thromboprophylaxis in multiple myeloma patients treated with lenalidomide \u2013a systematic review","volume":"141","author":"Al-Ani","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0015","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larr\u00e1n","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0020","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/bjh.12321","article-title":"Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study","volume":"161","author":"Alvarez-Larr\u00e1n","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.thromres.2003.10.013","article-title":"Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia","volume":"111","author":"Athale","year":"2003","journal-title":"Thromb. Res."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0030","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.thromres.2007.12.006","article-title":"Thromboembolism in children with lymphoma","volume":"122","author":"Athale","year":"2008","journal-title":"Thromb. Res."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0035","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2009-02-206797","article-title":"Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?","volume":"114","author":"Barbui","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0040","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0045","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European Leukemia Net","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0050","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0055","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/CCO.0b013e32834bb867","article-title":"How to manage thrombosis in myeloproliferative neoplasms","volume":"23","author":"Barbui","year":"2011","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0060","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1001\/jama.296.21.2558-c","article-title":"Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer","volume":"296","author":"Bennett","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3324\/haematol.2015.133900","article-title":"Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis","volume":"101","author":"Bever","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0070","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0075","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.leu.2404377","article-title":"Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features","volume":"21","author":"Breccia","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0080","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythemia and relation to polycythemia Vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0085","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0090","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","article-title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with Thalidomide and lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Carrier","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0095","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/jth.12338","article-title":"Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH","volume":"11","author":"Carrier","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0100","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1182\/blood-2006-04-015511","article-title":"Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients","volume":"108","author":"Caruso","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0105","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1538-7836.2007.02383.x","article-title":"Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis","volume":"5","author":"Caruso","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0110","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1182\/blood-2010-01-258624","article-title":"Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events","volume":"115","author":"Caruso","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0115","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/157016110791330799","article-title":"Thromboembolic complications in malignant haematological disorders","volume":"8","author":"Castelli","year":"2010","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0120","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/157016110791330799","article-title":"Thromboembolic complications in malignant haematological disorders","volume":"8","author":"Castelli","year":"2010","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0125","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jth.12652","article-title":"Kidney disease and risk of venous thromboembolism: a nationwide population- based case-control study","volume":"12","author":"Christiansen","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0130","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1053\/gast.2001.21209","article-title":"Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy","volume":"120","author":"Condat","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0135","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1365-2141.2005.05529.x","article-title":"Incidence of thrombotic complications in patients with hematological malignancies with central venous catheters: a prospective multicenter study","volume":"129","author":"Cortelezzi","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0140","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1200\/JCO.2005.10.192","article-title":"Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer","volume":"23","author":"Couban","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0145","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/MCP.0b013e3283553914","article-title":"Outcome of incidentally diagnosed pulmonary embolism in patients with malignancy","volume":"18","author":"den Exter","year":"2012","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0150","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1538-7836.2005.01467.x","article-title":"The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment","volume":"3","author":"De Stefano","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0155","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1538-7836.2007.02424.x","article-title":"Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders","volume":"5","author":"De Stefano","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0160","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments","volume":"93","author":"De Stefano","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0165","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3324\/haematol.13869","article-title":"Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia","volume":"94","author":"De Stefano","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0170","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period","volume":"12","author":"Deitcher","year":"2006","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0175","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.thromres.2013.08.007","article-title":"Infections increase the risk of central venous catheter related thrombosis in adult acute myeloid leukemia","volume":"132","author":"Del Principe","year":"2013","journal-title":"Thromb. Res."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0180","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1160\/TH06-09-0494","article-title":"Thalidomide and thrombosis. A meta-analysis","volume":"97","author":"El Accaoui","year":"2007","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0185","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00001721-200107000-00005","article-title":"Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia","volume":"12","author":"Elhasid","year":"2001","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0190","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia","volume":"128","author":"Elliot","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0195","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1200\/JCO.2009.22.8197","article-title":"Venous thromboembolism in the hematologic malignancies","volume":"27","author":"Falanga","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0200","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.thromres.2011.10.025","article-title":"Anticancer treatment and thrombosis","volume":"129","author":"Falanga","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0205","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM199709253371306","article-title":"The systemic amyloidoses","volume":"337","author":"Falk","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0210","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/13506129.2012.694825","article-title":"Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: a case report and literature review","volume":"19","author":"Freeman","year":"2012","journal-title":"Amyloid"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0215","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/j.seminoncol.2014.04.005","article-title":"Therapy for cancer-related thromboembolism","volume":"41","author":"Frere","year":"2014","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000046586","article-title":"Update on tumor cell procoagulant factors","volume":"106","author":"Gale","year":"2001","journal-title":"Acta Haematol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0225","first-page":"289","article-title":"Clotting alterations in primary systemic amyloidosis","volume":"85","author":"Gamba","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0230","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1600-0609.2006.00715.x","article-title":"Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications","volume":"77","author":"Gangat","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0235","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0240","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/cncr.11623","article-title":"High incidence of thromboembolism in patients with central nervous system lymphoma","volume":"98","author":"Goldschmidt","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0245","first-page":"967","article-title":"Cytokines and hemostasis","volume":"85","author":"Grignani","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0250","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/13506120500537285","article-title":"Natural history of thromboembolism in AL amyloidosis","volume":"13","author":"Halligan","year":"2006","journal-title":"Amyloid"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0255","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"United Kingdom medical research council primary thrombocythemia study: hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0260","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am. J. Med."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0265","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1111\/jth.12724","article-title":"Elevated risk of venous but not arterial thrombosis in Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma","volume":"12","author":"Hultcrantz","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0270","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1177\/030089160409000405","article-title":"Safety and efficacy of enoxaparin treatment in venous thromboembolic disease during acute leukemia","volume":"90","author":"Imberti","year":"2004","journal-title":"Tumori"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0275","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0280","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2215\/CJN.10131011","article-title":"Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease","volume":"7","author":"Kerlin","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0285","doi-asserted-by":"crossref","first-page":"E468","DOI":"10.1002\/ajh.24526","article-title":"Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia","volume":"91","author":"Khanal","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0290","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/cncr.21496","article-title":"Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study","volume":"104","author":"Khorana","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0295","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1200\/JCO.2005.03.8877","article-title":"Thromboembolism in hospitalized neutropenic cancer patients","volume":"24","author":"Khorana","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0300","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0305","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0310","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0315","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1182\/blood-2008-08-175745","article-title":"Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival","volume":"113","author":"Ku","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0320","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/CH-131691","article-title":"Hyperviscosity in plasma cell dyscrasias","volume":"55","author":"Kwaan","year":"2013","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0325","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0330","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/s-2007-994915","article-title":"The thrombophilic state induced by therapeutic agents in the cancer patient","volume":"25","author":"Lee","year":"1999","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0335","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0340","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs Warfarin for treatment of acute Venopus Thromboembolism in patients with active cancer. A randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0345","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.clml.2015.07.637","article-title":"Patterns of venous thromboembolism prophylaxis during treatment of acute leukemia: results of a North American web-based survey","volume":"15","author":"Lee","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0350","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.critrevonc.2016.06.011","article-title":"Safety of anticoagulation in the treatment of venous thromboembolism in patients with haematological malignancies and thrombocytopenia: report of 5 cases and literature review","volume":"105","author":"Lim","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0355","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","article-title":"Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review","volume":"124","author":"Lussana","year":"2009","journal-title":"Thromb. Res."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0360","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","article-title":"American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer","volume":"25","author":"Lyman","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2018.02.003_bib0365","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0049-3848(14)50004-7","article-title":"Lymphoma and venous thromboembolism: influence on mortality","volume":"133","author":"Mahajan","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0370","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0375","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0380","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/pbc.21222","article-title":"Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia","volume":"50","author":"Meister","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0385","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000098700","article-title":"Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: a single-center experience of 114 patients at diagnosis","volume":"117","author":"Melillo","year":"2007","journal-title":"Acta Haematol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0390","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0395","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood.V83.2.386.386","article-title":"Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in Asparaginase-induced antithrombin III deficiency","volume":"83","author":"Mitchell","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0400","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.11042","volume":"97","author":"Mitchell","year":"2003","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2018.02.003_bib0405","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0410","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/sj.bjc.6602504","article-title":"Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis","volume":"92","author":"Mohren","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0415","doi-asserted-by":"crossref","first-page":"e737S","DOI":"10.1378\/chest.11-2308","article-title":"Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Monagle","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0420","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.thromres.2008.09.008","article-title":"Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy","volume":"123","author":"Musallam","year":"2009","journal-title":"Thromb. Res."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0425","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3109\/10428194.2015.1046864","article-title":"Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study","volume":"57","author":"Napolitano","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0430","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1111\/j.1538-7836.2007.02660.x","article-title":"Prevention of catheter related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study","volume":"5","author":"Niers","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0435","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.3109\/10428194.2014.982640","article-title":"Treatment of catheter-related deep vein thrombosis in patients with acute leukemia with anticoagulation","volume":"56","author":"Oliver","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0440","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1600-0609.1995.tb00214.x","article-title":"Deep venous thrombosis and pulmonary artery embolis in high-grade non Hodgkin\u2019s lymphoma: incidence, causes and prognostic relevance","volume":"54","author":"Ottinger","year":"1995","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0445","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide and lenalidomide associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0450","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.blre.2010.08.002","article-title":"Thrombohemorragic complications of myeloproliferative disorders","volume":"24","author":"Papadakis","year":"2010","journal-title":"Blood Rev."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0455","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1470-2045(05)70207-2","article-title":"Cancer and venous thromboembolism","volume":"6","author":"Prandoni","year":"2005","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.02.003_bib0460","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/S0049-3848(07)70137-8","article-title":"Bleeding and thrombosis in acute leukemia: what does the future of therapy look like?","volume":"120","author":"Rickles","year":"2007","journal-title":"Thromb. Res."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0465","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ejvs.2008.11.030","article-title":"A randomised open label trial comparing long-term sub-cutaneous low-molecular weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis","volume":"37","author":"Romera","year":"2009","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2018.02.003_bib0470","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1016\/S0049-3848(16)30130-X","article-title":"OC-13 \u2013 safe and effective use of direct oral anticoagulants (DOAC) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism","volume":"140","author":"Ross","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0475","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/annonc\/mdh385","article-title":"The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance","volume":"15","author":"Sallah","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0480","first-page":"400","article-title":"Thrombosis in children receiving L-asparaginase. Determining patients at risk","volume":"15","author":"Shapiro","year":"1993","journal-title":"Am. J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0485","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cncr.20405","article-title":"Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease","volume":"101","author":"Srkalovic","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0490","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2011-04-347690","article-title":"Evidence-based focused review of management of hyperviscosity syndrome","volume":"119","author":"Stone","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0495","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-2004-823001","article-title":"Low-molecular-weight heparin in pediatric patients","volume":"30","author":"Sutor","year":"2004","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0500","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ajh.24037","article-title":"New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera","volume":"90","author":"Tefferi","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0505","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1200\/JCO.2010.31.9293","article-title":"Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer","volume":"29","author":"van Doormaal","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0510","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1200\/JCO.2005.06.084","article-title":"Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients","volume":"23","author":"Verso","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0515","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2016.143644","article-title":"Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial","volume":"101","author":"Verstovsek","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0520","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/cam4.332","article-title":"A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center","volume":"4","author":"Vu","year":"2015","journal-title":"Cancer Med."},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2018.02.003_bib0525","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/S0049-3848(10)70024-4","article-title":"Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma","volume":"125","author":"Wun","year":"2010","journal-title":"Thromb. Res."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0530","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/pbc.22146","article-title":"Varied opinions on thrombolysis for venous thromboembolism in infants and children: findings from a survey of pediatric hematology-oncology specialists","volume":"53","author":"Yee","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0535","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/jama.1983.03330340064034","article-title":"Bleeding manifestations in 100 patients with amyloidosis","volume":"249","author":"Yood","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0540","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/bjh.12168","article-title":"Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients","volume":"160","author":"Za","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2018.02.003_bib0545","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.thromres.2004.07.016","article-title":"Symptomatic venous thromboembolism in acute leukemia Incidence, risk factors, and impact on prognosis","volume":"115","author":"Ziegler","year":"2005","journal-title":"Thromb. Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817303645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817303645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T12:09:14Z","timestamp":1712491754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842817303645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":109,"alternative-id":["S1040842817303645"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.02.003","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}